Member access

4-Traders Homepage  >  Shares  >  Nyse  >  AbbVie Inc    ABBV   US00287Y1091

ABBVIE INC (ABBV)

40
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/28/2014 07/29/2014 07/30/2014 07/31/2014 08/01/2014 Date
53.74(c) 53.43(c) 53.75(c) 52.34(c) 52 Last
10 465 972 16 171 546 12 680 103 15 479 875 5 669 284 Volume
+1.05% -0.58% +0.60% -2.62% -0.65% Change
More quotes
Company
AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company's products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis... 
Sector
Pharmaceuticals
Calendar
10/24Earnings Release
Surperformance© rating of AbbVie Inc
Trading Rating : Investor Rating :
More about the company
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 19 606 M
EBIT 2014 6 848 M
Net income 2014 4 722 M
Debt 2014 4 780 M
Yield 2014 3,16%
Sales 2015 21 588 M
EBIT 2015 8 507 M
Net income 2015 6 011 M
Debt 2015 1 716 M
Yield 2015 3,44%
PER 2014 18,42
PER 2015 13,09
EV / Sales 2014 4,49x
EV / Sales 2015 3,94x
Capitalization 83 329 M
More Financials
Latest news on ABBVIE INC
1h ago ABBVIE : and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of..
1d ago AstraZeneca raises forecasts after seeing off Pfizer
2d ago Analysis - Ireland has too much to lose to deter U.S. companies re-homing
2d ago Ireland has too much to lose to deter U.S. companies re-homing
3d ago ABBVIE : Michael J. Fox Foundation Launches 'Partners in Parkinson's' Initiative
4d ago OBAMA COULD CURB CORPORATE 'INVERSIO : ex-U.S. official
6d ago ABBVIE : Assigned Patent
6d ago ABBVIE : FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as ..
6d ago ABBVIE : VP John Poulos Gets Licensing Executives Society Award
7d ago ABBVIE : profit beats estimates on surging Humira sales
07/25 ABBVIE : Reports Second-Quarter 2014 Financial Results
07/25 AstraZeneca results to get lift from bid foe Pfizer
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
AbbVie Inc : Income Statement Evolution
More Financials
EPS Revisions
AbbVie Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF